MS organisations battle for SPMS treatment to be available to those who need it. Draft guidelines challenged.
NHS
Vulnerability of MSers and Trump’s ‘reopen’ confusion
Confusion reigns across the world, especially among people with multiple sclerosis - and then there's Trump.
If HSCT is so safe, why haven’t I had it?
HSCT (Autologous Haematopoietic Stem Cell Transplantation) is an effective therapy to fight multiple sclerosis, the level of side effects is acceptable, and the therapy is safe, Ian Franks believes. Now, he answers the question why he has not undergone HSCT himself,
Ocrevus now approved UK-wide as an NHS treatment for early primary progressive MS
It will probably be no surprise, to regular readers, that I pay special attention to both the development and availability of treatments for PPMS (Primary Progressive Multiple Sclerosis). Ocrevus is now approved to treat early PPMS on NHS in all UK.
Give people with PPMS the treatment they need, MS Society campaign #SpeakupforMS
Blocking of a drug as a treatment for primary progressive multiple sclerosis (PPMS), making it unavailable for use by the UK’s National Health Service (NHS), is being challenged by the country’s MS Society. And it has coupled its opposition with a call to arms – inviting everyone to #SpeakupforMS. Holly, from the society’s campaigns community, … Continue reading Give people with PPMS the treatment they need, MS Society campaign #SpeakupforMS
Now Ocrevus blocked from health service in Scotland
Hot on the heels of NICE rejecting Ocrevus (ocrelizumab) as a treatment of PPMS by the National Health Service (NHS) in England, it has been blocked as a therapy for relapsing MS in Scotland. The Scottish Medicines Consortium (SMC) says it does not consider ocrelizumab to be cost effective for the NHS in Scotland as a treatment … Continue reading Now Ocrevus blocked from health service in Scotland
Ocrevus blocked again, this time for PPMS, as not cost-effective
So, news came out last week that the UK’s National Health Service will not be providing Ocrevus for treating primary progressive MS (PPMS) in England*. But, panic not, the decision is far from being set in stone. Why is this? Because the decision by the National Institute for Health and Care Excellence, (NICE), was … Continue reading Ocrevus blocked again, this time for PPMS, as not cost-effective
Threat to three DMTs removed after manufacturers cut prices
Manufacturers of three relapsing multiple sclerosis drugs have cut prices to remain available to Britain's National Health Service (NHS). They are all diseases modifying therapies (DMTs). In January, I brought you news that five such drugs were under threat, having been found to be not cost-effective as long-term therapy options. In a draft recommendation from … Continue reading Threat to three DMTs removed after manufacturers cut prices
MS drug Ocrevus could be barred from health service
Ocrevus may have taken the worldwide multiple sclerosis community by storm but it seems set for a rocky ride in the United Kingdom. It’s quite possible that it will not be available through the country’s National Health Service (NHS). Although the drug1, known by the non-brand name, ocrelizumab, was licensed by the European Medicines Agency … Continue reading MS drug Ocrevus could be barred from health service
MS bodies look for NICE support for PPMS treatment
Leading MS organisations are seeking support to gain approval for ocrelizumab (Ocrevus) to treat all primary progressive MS (PPMS). It is already approved for use against early PPMS. Both of the UK’s MS Society and MS Trust are campaigning to get the medication approved for wider use by the country’s National Health Service (NHS). And … Continue reading MS bodies look for NICE support for PPMS treatment
50shadesofsun 